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This study examined associations between polymorphisms in three genes, apolipoprotein E (APOE), angiotensin converting
enzyme (ACE), and vitamin D receptor (VDR), and longitudinal change in brain volumes and white matter lesions (WML) as
well as eﬀect modiﬁcation by cardiovascular factors and tibia lead concentrations. Two MRIs, an average of 5 years apart, were
obtained for 317 former organolead workers and 45 population-based controls. Both regions-of-interest and voxel-wise analyses
were conducted. APOE ε3/ε4a n dε4/ε4 genotypes were associated with less decline in white matter volumes. There was some
evidence of interaction between genetic polymorphisms and cardiovascular risk factors (ACE and high-density lipoprotein; VDR
and diabetes) on brain volume decline. The VDR FokI ﬀ genotype was associated with an increase in WML (no association for
APOE or ACE). This study expands our understanding of how genetic precursors of dementia and cardiovascular diseases are
related to changes in brain structure.
1.Introduction
Brain volume loss [1] and increase in white matter lesions
(WML)[2]arecommonconsequencesofaging,andbothare
related to worse cognitive function and risk of dementia [3–
6]. Little is currently known about the genetic determinants
of age-related brain volume loss or increase in WML or how
genes may modify the eﬀect of other environmental risk
factors for these outcomes. Certain genetic polymorphisms
associated with a greater risk for neurodegenerative diseases
such as Alzheimer’s disease (AD) in later life [7] are potential
candidates. The apolipoprotein E (APOE) gene is the best-
documented genetic risk factor for AD, with the ε4a l l e l e
signiﬁcantly increasing the risk for AD [8–10] and cognitive
decline [11]. The angiotensin converting enzyme (ACE)g e n e
is associated with AD [12, 13]a n dW M L[ 14]. Certain vita-
min D receptor (VDR) gene polymorphisms have also been
associated with increased risk of AD [15], cardiovascular
disease, and diabetes [16, 17], and these, in turn, have been
linked to WMLs [18, 19]. These genes are, therefore, strong
candidates for evaluation of genetic determinants of brain
volume loss and increased WML in living persons through
the useof neuroimaging technology. Furthermore, becauseit
is hypothesized that exposure to certain external agents may
induce upregulation of neurodegenerative disease-associated
genes[20],itisappropriatetoalsoexaminetheeﬀectofthese2 Journal of Aging Research
genes in the light of gene by environment interaction. Specif-
ically, well-known risk factors for neurodegenerative disease,
including cardiovascular risk factors and occupational lead
exposure, may modify the eﬀect of certain genotypes on
brain volume loss and WML.
Research has begun to evaluate relationships between
genetic risk factors and structural diﬀerences in the human
brain, the vast majority investigating APOE [21–31]. How-
ever, there are a number of limitations to this body of work,
including a reliance on cross-sectional data and extrapola-
tion of diﬀerences in structure across persons in diﬀerent
age ranges to within-person change. Many of these studies
also involve small sample sizes, limiting power to detect
diﬀerences, and some focus speciﬁcally on certain brain
structures such as the hippocampus rather than structures
across the whole brain. Furthermore, there has been little
examination of the eﬀect of gene by environment interaction
on structural brain changes. In this paper, we report on the
associations between APOE, ACE,a n dVDR FokI genetic
polymorphisms and longitudinal change in brain volumes
and WML from a cohort of over 350 older men who par-
ticipated in two structural MRIs an average of 5 years apart.
Additionally, because these genetic polymorphisms may not
directly contribute to changes in brain structure, but rather
may modify the eﬀect of other risk factors (i.e., gene by
environment interaction), we tested for interactions between
these genes and cardiovascular risk factors as well as oc-
cupational lead exposure in determining changes in brain
volumes and WML.
2. Methods
2.1. Study Design and Overview. As previously described
[32–34], subjects were initially recruited during two study
phases between 1994 and 2003. In phase I (1994–7), former
employees of a chemical manufacturing plant in the eastern
United States were identiﬁed and recruited. In phase II
(2001–3),additionalstudyparticipantswereenrolledandthe
ﬁrst MRI data was acquired. In phase III (2005–8), subjects
who completed the ﬁrst MRI were invited for a second
MRI. All phases of the study were reviewed and approved
by the Johns Hopkins Bloomberg School of Public Health
Committee on Human Research and written informed con-
sent was obtained from all participants.
2.2. Selection and Recruitment of Study Subjects. The selec-
tion, recruitment, and enrollment of former lead workers
and controls (community-dwelling persons without occupa-
tional lead exposure) have been previously reported [3, 32–
35]. During phase II, all participants were eligible for MRI
measurement, and ﬁrst MRIs were completed on 589 of 979
(60%) former lead workers and 67 of 131 (51%) controls.
During phase III, a second MRI was obtained from a total
of 377 persons: 317 of 589 (54%) former lead workers and
45 of 67 (67%) controls. Reasons for not obtaining a second
MRI are reported elsewhere [36]. The analytic cohort herein
includes the 309 former lead workers and 44 controls with
two adequate MRIs (n = 353; 8 former lead workers and 1
control had inadequate ﬁrst MRIs).
2.3. Data Collection. Detailed data collection methods for
the ﬁrst two phases of the study have been previously de-
scribed [34]. The remaining description is conﬁned to meas-
ures speciﬁcally used for the analysis presented herein.
2.3.1. Subject Interview. In phase III, the subject interview
was expanded to include a number of additional study
variables [37, 38]. Health outcomes (e.g., diabetes and heart
disease) were ascertained by interview response to the ques-
tion, “Has a doctor ever told you that you had (each con-
dition)?” Only “yes” responses were counted; participants
who answered “possible” were classiﬁed as negative for all
outcomes in order to increase speciﬁcity of outcome clas-
siﬁcation. For educational attainment, information was ob-
tained by interview on years of education, trade school, gen-
eral educational development (GED) credential, and other
educational certiﬁcates using previously published methods
[38].
2.3.2. Tibia Lead. Tibia lead, an estimate of lifetime cumula-
tive lead dose, was available from earlier phases of the study
on all former lead workers and all but one control with two
MRIs. For former lead workers, current tibia lead was back-
extrapolated to peak tibia lead, the estimated level at the
end of employment in the factory. The measurement of tibia
lead and this extrapolation to peak tibia lead are described
elsewhere [33].
2.3.3. Serum Tests. All serum assays were performed in the
Core Laboratory of the General Clinical Research Center
(Johns Hopkins Bayview Medical Center). C-reactive pro-
tein was measured by enzyme-linked immunosorbent assay
(ELISA) using the American Laboratory Products Company
(Salem, NH) kit, with a sample sensitivity of 0.5ng/mL, an
intrasample coeﬃcient of variation (CV) of 6.33% and an
intersample CV of 2.20%. The lipid proﬁle was performed
on a Medical Computer Systems analyzer with a sample
sensitivity of 0.80%, an intrasample CV of 3.08% and an
intersample CV of 3.72%.
2.3.4. Genotyping
APOE. Genotyping was completed using diﬀerent methods
in the diﬀerent phases of the study as technology progressed.
ThemethodofHixson[39]wasusedduringphaseI.Inphase
II, DNA was isolated using the Flexigene DNA Kit (Qiagen,
Valencia, Calif, USA), and genotyping was performed using
published PCR conditions [40, 41]. In phase III, DNA was
isolated as for phase II. For genotyping, for determination
of the C to T substitution causing the Arg112Cys and
Arg158Cys polymorphisms, we performed allelic discrimi-
nation using TaqMan Probes as previously described [41]
with the following modiﬁcations: (1) instead of using the
nested PCR approach for the Arg112Cys polymorphism, 1X
Genotyping Master Mix (Applied Biosystems, Foster City,
Calif, USA) was used with 20ng of genomic DNA and
processed according to the manufacturer’s recommended
protocol, (2) the 1X Genotyping Master Mix was also usedJournal of Aging Research 3
for the APOE Arg158Cys polymorphism, and (3) plate reads
wereperformedinthe7500RealTimePCRsystemtocapture
ﬂuorescence, and genotypes were determined by manual
clustering (Applied Biosystems 7500 software v1.2.3). Of the
subjects with two MRIs, APOE genotyping was performed
with the phase II method in 39.9% of subjects and with the
phase III method in 58.5% of subjects (the rest genotyped in
phase I).
ACE. We used a published PCR method to determine the
insertion/deletion polymorphism of the ACE gene [42]
with the following modiﬁcations: annealing time of 30
seconds and the ﬁnal concentrations: 0.4μmol/L primers,
1.5mmol/L MgCl, 200μM/L dNTPs, and 0.5U Taq. Frag-
ments were resolved on 2.5% agarose/TBE gels stained with
EtBr. Gels were imaged and photographed with a Fuji LAS
1000 system and analyzed with Fuji Multigauge version 3.0
software.
VDR. Genomic DNA was isolated as for a previous study
[41] from stored blood using the Flexigene DNA Kit from
Qiagen (Valencia, CA). For determination of the T to C sub-
stitution causing the VDR 12022 polymorphism (allowing
identiﬁcation of FF, Ff, and ﬀ genotypes), we performed
allelic discrimination using TaqMan Probes (Applied Biosys-
tems, Foster City, Calif, USA) using previously published
methods for single nucleotide polymorphisms [41]. Allelic
discrimination assays, consisting of primers and allele-
speciﬁc TaqMan MGB probes labeled with 6FAM and
Vic, were designed with Primer Express 2.0 and custom-
ordered from Applied Biosystems (sequences of primers
and probes available upon request). All reactions contained
1X assay mix, 1X TaqMan Genotyping MasterMix, and
20ng DNA in 25 microliters. Cycling was performed in the
Applied Biosystems 7500 Real Time PCR system with the
following conditions: 95◦C for 10 minutes and 50 cycles
of ampliﬁcation at 95◦C for 15 seconds and 60◦Cf o r1
minute. Following ampliﬁcation, plate reads were performed
as described above.
MRI Acquisition. For the ﬁrst MRI, all subjects were imaged
at the same location on the same General Electric 1.5 T
Signa model as previously described [34]. For the second
MRI, a 3 T General Electric scanner was utilized. T1-
weighted images were acquired using an SPGR sequence
(TE = 8ms, TR= 21ms, ﬂip angle = 30◦,F O V = 24cm).
Axial PD/T2 (TR/TE/TE2 = 2,200/27/120) and FLAIR
(TR/TE/T1 = 8,000/100/2000) images were also acquired for
WML grading.
Clinical MRI Review and Assignment of WML Grade Scores.
MRIs were reviewed to exclude urgent or emergent brain
disease and subjects and their physicians were notiﬁed if
present [43]. MRIs were assigned a WML grade score by
a trained neuroradiologist using the Cardiovascular Health
Study (CHS) ten-point (0 to 9) scale [44, 45], as previously
reported [34], which allowed for analysis of change in
ratings.
2.4. Image Analysis. The methods to obtain regional and
voxel-wise volumes, including skull stripping, segmentation,
registration, and transformation to regional analysis of
volumes examined in normalized space (RAVENS), were
completed using published methods [34, 36, 46–50]. Due
to changes in scanner technology and pulse sequences, we
employed specialized image analysis methods that mini-
mized the discontinuity between the two scans. We used the
CLASSIC algorithm [51], which employs a 4-dimensional
segmentation framework in which the baseline and follow-
up scans are considered jointly to minimize discrepancies
between the two segmentations and better estimate longitu-
dinal change. This algorithm has been previously validated
[51].
2.5. Statistical Analysis. The purpose of the present analysis
was to ﬁrst determine if genotypes for three diﬀerent can-
didate genes were associated with changes in brain volumes
and WML and then evaluate whether the genes modiﬁed
relationsofcardiovascularfactorsandtibialeadwithchanges
in brain volumes and WML. Multiple linear regression was
used to evaluate associations of the polymorphisms with
change in brain volumes using both ROI-based and voxel-
wise approaches as well as change in CHS scores (WML). All
regression models were adjusted for baseline age, duration of
time between MRIs, control status (i.e., former lead worker
versuscontrol),height(cm),andeducation[38]andbaseline
ROI volume for ROI analysis or baseline CHS score for the
WML analysis. Results were similar for models that did not
include terms for baseline ROI volume or CHS score (not
presented). Cross-product terms were used to evaluate eﬀect
modiﬁcation.
Because lead is associated with smaller brain volumes
[34], we ﬁrst evaluated whether the association between
genotypes and change in brain volumes or WML diﬀered
between former lead workers and population-based controls
or, within former lead workers, the associations of genotypes
with MRI outcomes diﬀered by peak tibia lead (PTL) level.
Therewasnoevidencethatassociationsofinterestdiﬀeredby
control status, so we proceeded with our main analyses using
data from both lead workers and controls. Furthermore,
a separate analysis found no association between PTL and
change in brain volumes [36]. We incorporated the results
of PTL by gene interactions in former lead workers into our
analyses as described below.
2.5.1. ROI-Based Approach. We modeled change in 20 pre-
viously selected ROI volumes consistent with our prior pub-
lished reports (as listed in Table 2)[ 34]. For bilateral struc-
tures, the volume represented the sum of right and left struc-
tures to minimize multiplicity concerns, but analyses were
also performed separately for change in left- and right-sided
ROI volumes (data not reported). We did not formallyadjust
for multiple comparisons in the analysis, choosing instead to
report unadjusted P values and the number of regressions.
We ﬁrst examined the relationship between each geno-
typeandchangeinROIvolumes(coremodels).Wethensep-
arately examined the relationships between cardiovascular4 Journal of Aging Research
risk factors (hypertension (HTN; yes versus no), cardiovas-
cular disease (CVD; yes versus no), diabetes mellitus (DM;
yes versus no), total cholesterol, high-density lipoprotein
(HDL), low-density lipoprotein (LDL), and C-reactive pro-
tein (CRP)) and change in brain volumes. To evaluate eﬀect
modiﬁcation by genotypes on relations of cardiovascular
risk factors with change in volumes or WMLs, we added
a term for cardiovascular risk factors (separately) and a
cross-product term for genotype ∗ risk factor to the core
models. Eﬀect modiﬁcation by genotypes on age relations
were also examined in separate models with a cross-product
term for genotype ∗ ageat baseline. We then examined eﬀect
modiﬁcation by genotype on the relationship of CHS score
at baseline, as well as change in CHS score across visits,
with change in ROI volumes. Finally, in former lead workers,
we examined interactions of PTL and genotypes on change
in ROI volumes. Model diagnostics were used to evaluate
inﬂuence and normality.
2.5.2. Voxel-Wise Approach. The relationship between geno-
types and change in voxel volumes was modeled controlling
for the aforementioned covariates using multivariate per-
mutation testing in the R statistical programming language
(http://www.cran.r-project.org/). The SPM5 package (Statis-
tical Parametric Software, Functional Imaging Laboratory,
Wellcome Department of Imaging Neuroscience, University
College London, 2003) was used to perform smoothing
using a 3D isotropic Gaussian ﬁlter and MRIcro [52]t o
display results. Statistical signiﬁcance was evaluated using
a permutation approach that controlled for confounding
variables. The maximum cluster size and cluster peak above
the threshold was used to deﬁne a conservative permutation
distribution on cluster sizes and peaks that, when compared
to the observed cluster sizes and peaks, controls for multiple
comparisons.
2.5.3. White Matter Lesions. Linear regression was used to
modelchangeinWMLgradescorescontrollingforcovariates
and evaluating the same eﬀect modiﬁcation variables. As
in the ROI-based analysis, we examined the relationships
between cardiovascular risk factors and change in WML,
and then eﬀect modiﬁcation by genotype on relationships
of cardiovascular risk factors with change in WML. Eﬀect
modiﬁcation by genotype on the relationship of age and
change in WML was also examined. In former lead workers,
we examined interactions of PTL and genotypes on change
in WML.
3. Results
3.1. Descriptive Summary of Study Subjects. Basic descriptive
characteristics of the 353 subjects with two valid MRIs are
presented elsewhere [36]. In short, the mean (SD) age was
65.1 (7.9) years (range: 48–82), 93% had a high school
education, and 90% were white. Seven subjects were missing
ACE genotyping, 6 subjects were missing ACE and VDR
genotyping, and 1 subject was missing data for ACE, VDR,
and APOE. With the exception of CRP by APOE genotype
and diabetes by VDR genotype, there were no diﬀerences
in distributions of cardiovascular risk factors by genotype
(Table 1). There were no diﬀerences in APOE, ACE,o rVDR
genotypes by control status (data not shown). There were no
diﬀerences in APOE or VDR genotypes by MRI status (i.e.,
zero versus one versus two MRIs; data not shown); we did
not perform ACE genotyping on persons without two MRIs.
Controls had signiﬁcantly lower mean (SD) levels of total
cholesterol (182.0 (31.5) versus 200.9 (40.8), P = 0.004) and
LDL (97.5 (29.4) versus 114.5 (34.8), P = 0.003), and higher
levels of CRP (3.3 (3.8) versus 2.4 (2.5), P = 0.04) than
former lead workers.
3.2. Change in ROI Volumes. As presented elsewhere in more
detail [36], the volumes of all ROIs except for occipital WM
declined from the ﬁrst to the second MRI over an mean (SD)
timeof5.0(0.4)years,withamoresubstantialdeclineingray
(−24.4cm3) versus white (−5.4cm3) matter. On average,
total brain volume declined an average of 30cm3.
Cardiovascular Risk Factors and WML. There was little
consistent evidence of a main eﬀect of cardiovascular risk
factorsonchangeinROIvolumes.However,higherHDLwas
associated with more decline in 5 ROI volumes: total brain
volume (β(SE) =− 0.183(0.078), P = 0.02), total WM (β
(SE) = −0.101 (0.047), P = 0.03), parietal WM (β (SE) =
−0.038 (0.011), P<0.001), cingulate gyrus (β (SE) = −0.009
(0.004), P = 0.01), and hippocampus (β (SE) = −0.004
(0.001), P = 0.006). More WML at baseline and change in
WML were not associated with change in ROI volume.
APOE. There were consistent associations of APOE geno-
type with change in ROI volumes (Table 2). Results are only
presented for the ε3/ε4a n dε4/ε4 genotypes combined, from
a model that also included terms for ε2/ε2p l u sε2/ε3a n d
ε2/ε4( w i t hε3/ε3 as the reference group). The positive beta
coeﬃcients indicate less decline for those with the ε3/ε4o r
ε4/ε4 genotypes (e.g., the TBV for persons with the ε3/ε4
or ε4/ε4 genotypes declined an average of 23cm3 versus
31cm3 for persons with the ε3/ε3g e n o t y p e( Figure 1)). The
diﬀerences in ROI volume declines by APOE genotype were
largest and most consistent for changes in white matter
volumes.
There was evidence that APOE genotype modiﬁed
relations of age with change in ROI volumes. Persons who
were older at baseline and had the ε3/ε4o rε4/ε4g e n o t y p e
experienced more decline in the following ROI volumes:
frontal WM (β (SE) = −0.207 (0.086), P = 0.02), parietal
WM(β (SE) = −0.115(0.048),P = 0.02),corpuscallosum(β
(SE) = −0.023 (0.007), P = 0.001), hippocampus (β (SE) =
−0.013 (0.006), P = 0.02), and amygdala (β (SE) = −0.008
(0.003), P = 0.02) (frontal WM displayed in Figure 2.T h e r e
were no consistent interactions between cardiovascular risk
factors and genotype for change in any ROI volume.
We next evaluated whether relations among change in
WML and change in ROI volumes were modiﬁed by APOE
genotype. In models that included terms for change in WML
and a cross-product for APOE genotype ∗ change in WML,Journal of Aging Research 5
Table 1: Distribution of cardiovascular risk factors by genotype.














APOE (n = 352)1
ε2/ε3+ε2/ε2 46 (14) 20 (43) 11 (24) 10 (22) 196.7 (49.4) 52.7 (15.6) 107.0 (41.9) 2.7 (2.6)
ε3/ε3 214 (61) 116 (54) 23 (11) 39 (18) 198.8 (39.7) 50.2 (13.9) 111.8 (34.4) 2.7 (2.9)
ε2/ε4 11 (3) 6 (55) 2 (18) 0 (0) 196.9 (39.8) 44.3 (14.8) 121.3 (27.6) 2.5 (2.6)
ε3/ε4+ε4/ε4 81 (23) 42 (52) 9 (11) 15 (19) 199.2 (36.6) 48.3 (12.9) 116.2 (31.2) 1.7 (1.8)
P = 0.62 P = 0.094 P = 0.42 P = 0.99 P = 0.19 P = 0.43 P = 0.02
ACE (n = 339)2
I/I 64 (19) 38 (59) 8 (13) 10 (16) 200.2 (38.9) 52.5 (14.9) 111.9 (34.7) 2.1 (1.8)
I/D 137 (40) 67 (49) 12 (9) 26 (19) 196.7 (39.0) 49.8 (13.3) 112.0 (31.8) 2.4 (2.6)
D/D 138 (41) 74 (54) 22 (16) 25 (18) 198.9 (42.6) 48.7 (14.4) 112.5 (37.7) 2.7 (2.9)
P = 0.37 P = 0.20 P = 0.85 P = 0.82 P = 0.20 P = 0.99 P = 0.32
VDR (n = 346)
FF 125 (36) 60 (48) 17 (14) 15 (12) 198.6 (39.1) 49.4 (14.8) 111.9 (33.3) 2.4 (2.7)
Ff 168 (49) 90 (54) 19 (11) 34 (20) 199.1 (40.9) 49.5 (13.7) 114.0 (36.0) 2.6 (2.7)
ﬀ 53 (15) 31 (58) 8 (15) 14 (26) 197.3 (42.6) 52.2 (13.1) 109.3 (34.4) 1.9 (2.2)
P = 0.40 P = 0.72 P = 0.047 P = 0.96 P = 0.43 P = 0.68 P = 0.21
1Certain genotypes were combined for analysis, resulting in following analytic groups: (1) ε3/ε4a n dε4/ε4, (2) ε2/ε2a n dε2/ε3, (3) ε2/ε4, (4) ε3/ε3 (reference
group). 2I: insertion, D: deletion.
t h e r ew a se v i d e n c eo fs u c he ﬀect modiﬁcation. Persons who
had APOE ε3/ε4o rε4/ε4 genotype and an increase in WML
experienced less decline in the following ROI volumes; total
brain volume (β (SE) = −6.658 (2.402), P = 0.006), total
WM (β (SE) = −3.727 (1.419), P = 0.009), frontal WM
(β (SE) = −1.717 (0.611), P = 0.005), temporal WM (β
(SE) = −0.806 (0.358), P = 0.03), parietal WM (β (SE) =
−1.183 (0.341), P = 0.001), medial structures (β (SE) =
−0.802(0.304),P = 0.009),cingulategyrus(β (SE) = −0.251
(0.116), P = 0.03), insula (β (SE) = −0.242 (0.081), P =
0.003), corpus callosum (β (SE) = −0.117 (0.052), P = 0.03),
internal capsulate (β (SE) = −0.125 (0.048), P = 0.01), and
hippocampus (β (SE) = −0.139 (0.040), P = 0.001) (see,e.g.,
Figure 3).
ACE. There were no associations between ACE genotype
and change in ROI volumes. There was no evidence that
ACE genotype modiﬁed relations of age with change in ROI
volumes. There was evidence that ACE genotype modiﬁed
relations of HDL with change in ROI volumes. Persons with
greater HDL who had the I/I genotype experienced less
decline in the following ROIs: total brain volume (β (SE) =
0.533 (0.211), P = 0.01), total WM (β (SE) = 0.342 (0.127),
P = 0.007), frontal WM (β (SE) = 0.131 (0.055), P = 0.02),
parietal WM (β (SE) = 0.080 (0.030), P = 0.009), occipital
WM(β (SE) =0.034(0.017),P = 0.04),andhippocampus(β
(SE) = 0.007 (0.004), P = 0.04). There was no evidence that
ACE genotype modiﬁed relations of any other cardiovascular
risk factors or WML scores with change in ROI volumes.
VDR. There were no associations between VDR genotype
and change in ROI volumes. There was no evidence that
VDR genotype modiﬁed relations of age with change in ROI
volumes. There was evidence that VDR genotype modiﬁed
relations of diabetes with change in ROI volumes. Persons
who had diabetes and were heterozygous for the VDR FokI
Ff genotype experienced less decline in the following ROIs:
total WM (β (SE) = 9.873 (4.102), P = 0.02), frontal WM
(β (SE) = 3.557 (1.755), P = 0.04), temporal WM (β (SE) =
2.412 (1.013), P = 0.02), occipital WM (β (SE) = 1.281
(0.537), P = 0.02), internal capsule (β (SE) = 0.336 (0.137),
P = 0.02),andentorhinalcortex(β (SE) =0.153(0.062),P =
0.01). There was no consistent evidence that VDR genotype
modiﬁed relations of any other cardiovascular risk factors
with change in ROI volumes. There was evidence that VDR
modiﬁed relations of change in WML scores and change in
ROI volumes. Persons who were homozygous for the VDR
FokI ﬀ genotype and had an increase in WML experienced
more decline in the following ROI volumes: total GM (β
(SE) = −4,570 (2.089), P = 0.03), frontal GM (β (SE) =
−1.402(0.604),P = 0.02),andparietalGM(β (SE) = −0.696
(0.319), P = 0.03), but less decline in two ROIs: frontal WM
(β (SE) = 1.513 (0.723), P = 0.04), and parietal WM (β
(SE) = 0.895 (0.401), P = 0.03).
Lead By Gene Interaction. In former lead workers, there
was little evidence that PTL modiﬁed the relationship of
candidate genes with change in ROI volumes. A signiﬁcant
interaction of PTL with APOE ε3/ε4o rε4/ε4g e n o t y p ew a s
foundinonlyoneROI,occipitalGM(β (SE) =0.031(0.016),
P = 0.045).
Change in Voxel Volumes. In a parallel analysis, results were
substantivelysimilarusingavoxel-wiseapproach.Thesupra-
threshold clusters for the association of ACE genotype and
VDR genotype with change in GM and WM volume were6 Journal of Aging Research
Table 2: Regressiona results for delta ROI models for former lead workers and controls (N = 352), adjusting for confounding variables.
APOE ACE VDR
ε3/ε4+ε4/ε4c I/D, I/Id Ff, ﬀe
ROIb Beta (SE) Beta (SE) Beta (SE)
TBV 8.045 (2.621)∗∗∗ 4.498 (2.477) −2.709 (3.134) 2.188 (2.429) 0.537 (3.373)
TOTAL GM 3.320 (1.975)∗ 2.135 (1.839) −1.236 (2.328) 1.733 (1.806) −0.038 (2.508)
FRONT GM 1.076 (0.575)∗ 0.645 (0.534) −0.591 (0.677) 0.585 (0.524) 0.288 (0.729)
OCCIP GM 0.241 (0.213) 0.187 (0.198) −0.083 (0.251) 0.254 (0.194) 0.106 (0.271)
PARI GM 0.612 (0.301)∗∗ 0.636 (0.282)∗∗ −0.041 (0.357) 0.104 (0.276) −0.011 (0.383)
TEMP GM 0.619 (0.485) 0.677 (0.457) 0.046 (0.578) 0.709 (0.443) −0.063 (0.616)
TOTAL WM 5.059 (1.554)∗∗∗ 2.402 (1.491) −1.398 (1.887) 0.548 (1.451) 0.309 (2.012)
FRONT WM 2.331 (0.666)∗∗∗ 0.839 (0.639) −0.825 (0.309) −0.080 (0.623) −0.248 (0.864)
OCCIP WM 0.818 (0.203)∗∗∗ 0.176 (0.195) −0.051 (0.246) 0.140 (0.190) 0.052 (0.263)
PARI WM 0.921 (0.374)∗∗ 0.378 (0.358) −0.291 (0.452) 0.071 (0.347) 0.111 (0.481)
TEMP WM 0.557 (0.389) 0.242 (0.367) −0.477 (0.464) −0.148 (0.358) 0.130 (0.495)
ERC 0.032 (0.024) 0.008 (0.023) 0.016 (0.029) −0.001 (0.022) −0.013 (0.031)
AMYG 0.035 (0.024) 0.033 (0.023) −0.043 (0.029) 0.013 (0.022) −0.039 (0.031)
HIPPO 0.070 (0.044) 0.044 (0.042) −0.020 (0.053) 0.050 (0.040) 0.057 (0.056)
CEREB 0.102 (0.473) 0.158 (0.447) −0.043 (0.568) 0.650 (0.432) 0.447 (0.598)
MEDIAL 0.898 (0.332)∗∗∗ 0.231 (0.315) −0.361 (0.396) 0.207 (0.306) 0.044 (0.424)
INSULA 0.128 (0.088) 0.092 (0.083) −0.146 (0.104) 0.010 (0.081) −0.051 (0.113)
CINGULATE 0.236 (0.124)∗ 0.149 (0.116) −0.047 (0.147) 0.050 (0.114) −0.107 (0.159)
CORP CALL 0.055 (0.057) 0.005 (0.054) 0.039 (0.068) −0.029 (0.052) −0.033 (0.072)
INT CAPS 0.151 (0.052)∗∗∗ −0.002 (0.050) −0.059 (0.064) −0.028 (0.049) −0.058 (0.068)
∗0.05 < P < 0.10; ∗∗0.01 < P < 0.05; ∗∗∗P < 0.01.
aModels adjusted for height, baseline ROI, control status, duration between MRIs, and education.
bROI: region of interest; TBV: total brain volume (TBV1 = TBV at ﬁrst MRI); GM: gray matter; FRONT: frontal; OCCIP: occipital; PARI: parietal; TEMP:
temporal; WM: white matter; ERC: entorhinal cortex; AMYG: amygdala; HIPPO: hippocampus; CEREB: cerebellum; MEDIAL: medial structures (bilateral
amygdala, cuneus, entorhinal cortex, hippocampal formation, lingual gyrus, medial front-orbital gyrus, medial frontal gyrus, medial occipitotemporal gyrus,
parahippocampal gyrus, perirhinal cortex, precuneus, and uncus); CORP CALL: corpus callosum; INT CAPS: internal capsule.
cCompared to APOE3-3 as reference group; model also included terms for 22 + 23 and 24.
dCompared to D/D (homozygous for deletion) as reference group.
eCompared to FF as reference group.
within the range expected by chance (not shown). The
adjusted association between APOE ε3/ε4o rε4/ε4g e n o t y p e
and change in voxel volumes identiﬁed large supra-threshold
clusters in WM, whose sizes were above the distribution of
the maximum cluster size under the null hypothesis (largest
association cluster depicted in Figure 4).
3.3. Change in WML Grade Score. Summary statistics for
change in CHS WML scores between the ﬁrst and second
MRI have been previously reported [36]. In brief, 74%
of the sample showed increased WML over followup. The
APOE and ACE genotypes were not associated with changes
in WML scores. In adjusted analysis, controlling for age,
duration between MRIs, control status, height, education,
and baseline CHS score, the VDR FokI polymorphism was
associated with increases in WML in a gene-dose-dependent
f a s h i o n ,w i t hb e t ac o e ﬃcients (SE, P-value) of 0.18 (0.12,
P = 0.13) and 0.45 (0.16, P = 0.006) for Ff and ﬀ genotypes,
respectively. This indicates, for example, that, on average,
subjects with the ﬀ genotype had CHS scores that increased
0.45 categories higher than did those with the FF genotype
(Figure 5). These associations did not change when baseline
CHS score was removed from the model. In former lead
workers, there was no evidence of interactions of genes with
PTL.
4. Discussion
In this cohort of nondemented older men with two MRI
scans an average of ﬁve years apart, we examined relations
of three genetic polymorphisms with longitudinal change
in brain volumes and WMLs, Our main ﬁndings were that
the APOE ε3/ε4a n dε4/ε4 genotypes were associated with
less decline in brain volumes over time, especially in WM,
and that these genotypes modiﬁed the relationship of age
as well as change in WML with change in brain volumes.
We also found that the VDR FokI ﬀ genotype was associated
with an increase in WMLs. There was some evidence that
the genotypes modiﬁed relations of cardiovascular risk
factors with change in both ROI volumes and WMLs, but
these ﬁndings were not consistent across brain regions or
consistent across risk factors. There was no evidence that
genotypes modiﬁed relations of lead levels with change in































































e3/e3 e3/e4 and e4/e4
APOE genotype

















Figure 1: Change in total brain, GM, and WM volumes by APOE genotype. The grey and black lines are estimated change in volumes
(mean±95% conﬁdence interval) for the APOE ε3/ε3a n dAPOE ε3/ε4+ε4/ε4 groups, respectively. The asterisk indicates that the estimated
change for the ε3/ε4+ε4/ε4 group is signiﬁcantly diﬀerent than for the ε3/ε3 group (P < 0.05).
ﬁndings give us some insight into the genetic determinants
of structural changes in the brain that may contribute to
cognitive impairments in later life.
A number of studies have examined the relation between
APOE genotype and brain structure. The ε4a l l e l eh a sb e e n
associated with smaller total brain, gray matter, hippocam-
pus, amygdala, and corpus callosum volumes, and more
WMLs [21–24]. However, there are a number of studies
that have found no association between APOE and brain
volumes [25, 26]o rW M L[ 26] in healthy samples, and at
least three studies in AD patients have found an association
between ε4a n dlarger volumes [27–29]. The majority of
these studies used cross-sectional study designs in which
changeinstructurevolumesacrossagerangesisextrapolated
from inter-individual diﬀerences in age. Very little research
has focused on how these genetic risk factors relate to
longitudinal intraindividual changes in brain structure. In
nondemented cohorts, one longitudinal study found an
association of the ε4 allele with greater hippocampus volume
loss [30], while another found a nonsigniﬁcant trend for
a relation between the ε4 allele and greater brain atrophy
[31]. One longitudinal study on APOE genotype and WMLs
h a sb e e nc o n d u c t e d ,w h i c hf o u n da ni n c r e a s ei nW M L si n
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Figure 2: Eﬀect modiﬁcation by APOE genotype on relation of age
with change in frontal WM volume for APOE ε3/ε3( b l a c kd o t s ,
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Figure 3: Eﬀect modiﬁcation by APOE genotype on relation of
change in WML and change in total brain volume for APOE ε3/ε3
(black dots, solid regression line) and ε3/ε4p l u sε4/ε4 groups
(triangles, dashed regression line). The slopes of the two lines were
diﬀerent (P < 0.05).
research on ACE polymorphisms and diﬀerences in brain
structure. One study found an association between the I/I
genotype and smaller hippocampus and amygdala volumes
in women only, but no association with WML [54]a n d
another found no relation to volume or WML [55]. A
recentreviewfoundevidenceofassociationbetweenACE I/D
Figure 4: Largest signiﬁcant clusters where APOE ε4/ε4o rε3/ε4
genotypes were associated with less decline in WM volume for
statistical maps based on family-wise error rate corrected P value
thresholding from permutation testing. Results are shown for
relevant coronal (upper left), sagital (upper right) and axial (lower)
slices. Statistical signiﬁcance was based on suprathreshold cluster-
level permutation testing. Colors represent voxels satisfying P value
thresholds of 0.001, 0.0001, and 0.00001, respectively.
polymorphism and WML from 9 cross-sectional studies,
but cautioned against publication bias [56]. We were unable
to identify any prior studies of VDR genotype and brain
structure.
Our results are not consistent with the small number of
studies that have previously examined the relations between
the APOE ε4 allele and change in brain volumes in nonde-
mented cohorts. We found that subjects with the ε4a l l e l e
had less rather than more decline in volumes of brain
structures compared to those without the allele. This ﬁnding
is unexpected in light of the established relation between
the ε4 allele and neurodegenerative diseases such as AD and
the concomitant brain atrophy experienced by individuals
who have these diseases. However, given the paucity of
evidenceregardingthisrelationship, theseﬁndingsshouldbe
treated as preliminary and may suggest a diﬀerent pathway
from gene to AD expression as mediated through structural
changes in the brain than have been previously recognized.
For example, the association between ε4 and less decline in
volume was strongest in WM; this could be consistent with
an adverse eﬀect in persons with the ε4 allele if the slower
rate of WM volume loss is due to inﬂammation, edema,
swelling of cells, or other changes in WM that are present
in early lesions in these relatively young study subjects [57].
This hypothesis may be supported by the accompanying
ﬁnding that higher levels HDL, usually considered protective
against vascular events, was associated with more WM
decline as well. Alternatively, these ﬁndings may align with
the emerging theory of APOE antagonistic pleiotropy in
whichtheε4alleleconfersanadvantageatyoungerageswhile





















Figure 5: Change in WML grade score by VDR FokI genotype.
The light gray, dark gray, and black lines are for groups with the
FF, Ff, and ﬀ genotypes, respectively. The asterisk indicates that
the estimated change in WML scores for genotype was signiﬁcantly
diﬀerent from the FF genotype.
life [58]. This is supported by our ﬁnding of an interaction
between age and ε4 status on WM decline in which persons
with ε3/ε4o rε4/ε4 genotype experience less decline than
ε3/ε3 carriers at earlier ages, but this diﬀerence attenuates
and actually reverses after the age of 70, after which ε3/ε4
or ε4/ε4 experience more decline. Further, there is evidence
that APOE antagonistic pleiotropy is related to integrity of
the cholinergic system [59]; the most robust associations
between ε3/ε4o rε4/ε4 genotype and less decline was found
in the basal forebrain (Figure 4), a region considered to be
the major cholinergic output of the brain.
We also observed eﬀect modiﬁcation by APOE genotype
on the relation of change in WML with change in brain vol-
umes.Personswithε3/ε4orε4/ε4genotypesexperiencemore
decline in brain volumes with increases in WML. Notably,
cardiovascularriskfactorswerenotassociatedwithincreased
WML, perhaps indicating that both decline in WM and
progression of WML may not have linear relationships with
traditional risk factors for cognitive impairment over the life
course. Finally, our study is the ﬁrst to report on an asso-
ciation between VDR FokI genotype and change in WML.
This ﬁnding needs to be replicated before any conclusions
can be drawn, but connections between VDR, cardiovascular
disease, and WMLs gives this ﬁnding biological plausibility
[16, 19].
The study had several strengths, including larger sample
size than most prior studies, longitudinal design, use of
ROI-based and voxel-wise analyses, relatively long duration
between scans, and analysis of WMLs as determined by
application of the CHS WML grading method. The main
strength of this study was the ability to examine intrain-
dividual change in brain structures over a 5-year period
using longitudinal data. This provides a more valid measure
of change and predictors of change than extrapolating an
estimate of change from separate individuals across a range
of ages using cross-sectional data.
A limitation of this study is the selected nature of
the cohort, which was made up entirely of men, most of
whom had histories of occupational lead exposure. However,
general population samples have shown tibia lead levels sim-
ilar to this cohort [60, 61], consistent with documentation
that all Americans over the age of 50 years had signiﬁcant
environmental lead exposure [62]. Thus, our ability to adjust
for and examine interactions with lead is also a strength of
this study. The fact that prior studies of older Americans
have not considered this ubiquitous neurotoxicant that
inﬂuences brain volumes [34] could be an important source
of confounding. The ubiquity of lead exposure could also
mask a potential gene by lead interaction, resulting in a gene
appearingtoexertamaineﬀect[63].However,agenebylead
interaction was not observed for change in brain volumes or
increase in WML.
An important consideration that could aﬀect the internal
validity of these results is selection bias, as persons who had
an MRI scan may not be representative of the total cohort.
In previous papers, we reported that there was unlikely to
be meaningful selection bias, and if present, would likely
mask rather than spuriously create associations [34, 36].
A methodological challenge was changes in the scanner
technology between the two MRI scans. We attempted to
minimize the problems introduced by these changes by using
an image analysis technique that was speciﬁcally developed
and validated for longitudinal studies that is more likely to
underestimate rather than overestimate longitudinal brain
changes [51].
In conclusion, this analysis adds to the emerging body of
literature on genetic contributions to brain changes in later
life. The ﬁndings suggest that early WM lesions in middle-
aged persons with the APOE ε4 allele may initially be space-
occupying, due to inﬂammation, edema, or swelling of cells,
but that with advancing age and increases in WM lesions,
persons with the ε4a l l e l ee x p e r i e n c em o r ev o l u m el o s s .T h i s
analysisisalsooneoftheﬁrsttoshowanassociationbetween
VDR genotype and changes in WM lesions.
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